Syneos acquires consulting firm to boost regulatory, safety, pharmacovigilance capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags: Syneos Health, Regulation, Safety, Pharmacovigilance, Commercialization

Syneos Health has acquired the UK-based advisory firm Kinapse in a deal that will double its consulting footprint in Europe and further strengthen its commercial offerings – one company's fastest-growing lines of business, says CEO.

Established in 2005, Kinapse provides services across clinical and commercial development. According to Syneos​, Kinapse’s capabilities will expand its post-market regulatory, safety, and pharmacovigilance consulting and operations.

The deal also bolsters Syneos’ clinical trial transparency, medical writing and quality operations and consulting capabilities in R&D and clinical operations, medical affairs, market access, and quality and compliance.

Additionally, the UK-headquartered company has more than 600 staff located in Europe, India, and the US – increasing Syneos’ capabilities in Asia Pacific and doubling its consulting footprint in Europe.

Kinapse operations will be integrated into Syneos’ consulting business.

Read more: Commercial Trends Forecast: ‘R&D is transforming into R&D&C’

The acquisition – terms of which were not disclosed – was funded through cash on hand.

As part of the announcement, Syneos reaffirmed its 2018 guidance range provided​ earlier this month. Also on the second quarter earnings call​, Syneos CEO Alistair Macdonald said the company’s commercial strategy consulting services represents one of its fastest-growing lines of business.

The company reported total net awards of $1.1bn, which included multiple new strategic relationships, driven by collaboration and cross-selling across the clinical and commercial organizations, he said.

Regarding the Kinapse acquisition, Macdonald said the company is “poised to further strengthen”​ its commercial business by integrating Kinapse’s services into “more comprehensive offerings.”

“As customers increasingly face risk, competition and rising development costs, the innovative, technology-enabled solutions provided by Kinapse are seeing increasing demand,”​ he said in a press release.

Syneos is not providing any further comment at this time.

Related news

Show more

Related products

show more

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us


View more